A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

Turkish Journal of Internal Medicine
Volume:3 Issue:Supplement 1 Special Issue
A case report of euglycemic ketoacidosis due to dapagliflozin treatment

A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Authors : Murat ÇALAPKULU, Muhammed Erkam SENCAR, İlknur ÖZTÜRK ÜNSAL, Hayri BOSTAN, Erman ÇAKAL

Pages : 85-86

Doi:10.46310/tjim.877156

View : 43 | Download : 11

Publication Date : 2021-03-07

Article Type : Other Papers

Abstract :Diabetic ketoacidosis insert ignore into journalissuearticles values(DKA); is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter insert ignore into journalissuearticles values(SGLT-2); inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.
Keywords : Dapagliflozin, sodium glucose co transporter 2 inhibitors, euglycemic ketoacidosis

ORIGINAL ARTICLE URL

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.